{"url":"https://lda.senate.gov/api/v1/filings/538c320d-e008-45dd-b647-e6cc5e470a0e/","filing_uuid":"538c320d-e008-45dd-b647-e6cc5e470a0e","filing_type":"Q2","filing_type_display":"2nd Quarter - Report","filing_year":2024,"filing_period":"second_quarter","filing_period_display":"2nd Quarter (Apr 1 - June 30)","filing_document_url":"https://lda.senate.gov/filings/public/filing/538c320d-e008-45dd-b647-e6cc5e470a0e/print/","filing_document_content_type":"text/html","income":"60000.00","expenses":null,"expenses_method":null,"expenses_method_display":null,"posted_by_name":"Edward B Stewart","dt_posted":"2024-07-17T19:02:28-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"1333 H Street NW","registrant_address_2":"Suite 800E","registrant_different_address":false,"registrant_city":"Washington","registrant_state":"DC","registrant_zip":"20005","registrant":{"id":401104254,"url":"https://lda.senate.gov/api/v1/registrants/401104254/","house_registrant_id":43449,"name":"NOVEL STRATEGIES (FKA) PRISM GROUP","description":"A public affairs and government relations firm.","address_1":"1331 Pennsylvania Avenue, NW","address_2":"Suite 400 South","address_3":null,"address_4":null,"city":"Washington","state":"DC","state_display":"District of Columbia","zip":"20004","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"EDWARD STEWART","contact_telephone":"+1 202-683-4079","dt_updated":"2026-04-17T16:41:47.330027-04:00"},"client":{"id":56155,"url":"https://lda.senate.gov/api/v1/clients/56155/","client_id":56155,"name":"GENEVANT SCIENCES, INC.","general_description":"Business/legal/admin.for tech-focused nucleic acid development and delivery company","client_government_entity":null,"client_self_select":false,"state":"MA","state_display":"Massachusetts","country":"US","country_display":"United States of America","ppb_state":"MA","ppb_state_display":"Massachusetts","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2023-05-05"},"lobbying_activities":[{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"Healthcare matters","foreign_entity_issues":"Per initial registration: Genevant Sciences Holdings Limited (GSHL) Main address: United Kingdom (GBR) Principal place of business: United Kingdom (GBR) Genevant Sciences Ltd. (GSL) Main address: Bermuda (BER) Principal place of business: United Kingdom (GBR) Roivant Sciences Ltd Main address: Bermuda (BER) Principal place of business: United Kingdom (GBR)","lobbyists":[{"lobbyist":{"id":65058,"prefix":null,"prefix_display":null,"first_name":"JOHN","nickname":null,"middle_name":null,"last_name":"STANFORD","suffix":null,"suffix_display":null},"covered_position":"n/a","new":false},{"lobbyist":{"id":71441,"prefix":null,"prefix_display":null,"first_name":"JAY","nickname":null,"middle_name":"BRETT","last_name":"PERRON","suffix":null,"suffix_display":null},"covered_position":"n/a","new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]}